Since May 1 Regeneron Pharmaceuticals’ stock has been rising from $525.50 to $576.72 as we see it at the close of May 15. Q1 2020 revenue does not show improvement compared to Q4 2019’s. However, total and interest expenses became lower than the previous quarter’s. Eventually, EBIT decreased significantly to $674.700.000.
Like other pharmaceutical companies, Regeneron is making efforts to stop the pandemic by trying its Kevzara (sarilumab) medicine to fight the COVID-19. So far, the antibody medicine is under development. Confident investors are hopefully pouring their funds to help the giant pharmaceutical company to create the cure that will take months. Following this scenario, other opportunity seekers may take a great advantage as the stock slowly grows.